Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 11/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1921293 | 0.82 | RAPGEF4 (0.57) | RAPGEF4PTGS2ALDH1A1HTR1DPOLB | |
| SCHEMBL2927525 | 0.81 | ALDH1A1 (0.54) | RAPGEF4PTGS2ALDH1A1HTR1DPOLB | |
| SCHEMBL4800221 | 0.80 | RAPGEF4 (0.55) | RAPGEF4PTGS2ALDH1A1RAB9A | |
| SCHEMBL12152328 | 0.76 | LMNA (0.40) | RAPGEF4ALDH1A1LMNACYP3A4CYP2D6 | |
| SCHEMBL3631643 | 0.75 | RAPGEF4 (0.59) | RAPGEF4ALDH1A1POLB | |
| SCHEMBL14168981 | 0.75 | RAPGEF4 (0.75) | RAPGEF4 | |
| SCHEMBL23193120 | 0.75 | PTGS2 (0.50) | RAPGEF4PTGS2ALDH1A1HTR1DPOLB | |
| SCHEMBL3978752 | 0.74 | RAPGEF4 (0.55) | RAPGEF4PTGS2ALDH1A1 | |
| SCHEMBL4278475 | 0.74 | ALDH1A1 (0.72) | RAPGEF4ALDH1A1HTR1DPOLBLMNA | |
| SCHEMBL4097984 | 0.73 | L3MBTL1 (0.39) | RAPGEF4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230680-A1 | LUBRICATING COMPOSITIONS CONTAINING ASHLESS CATALYTIC ANTIOXIDANT ADDITIVES | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2011-09-22 | — | — | US | disclosed |
| US-7977286-B2 | Substituted N,N'-diaryl-m-phenylenediamines impart good levels of oxidation inhibition in lubricants, hydraulic fluids; lubricant is a synthetic oil derived from a Fischer-Tropsch wax via palladium/phosphine complex coupling catalyst; engine, industrial, marine, hydraulic, aviation, driveline oils | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2011-07-12 | — | — | US | disclosed |
| EP-2029706-A2 | LUBRICATING COMPOSITIONS CONTAINING ASHLESS CATALYTIC ANTIOXIDANT ADDITIVES | ExxonMobil Research and Engineering Company (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007133462-A2 | LUBRICATING COMPOSITIONS CONTAINING ASHLESS CATALYTIC ANTIOXIDANT ADDITIVES | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070265178-A1 | Lubricating compositions containing ashless catalytic antioxidant additives | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265178-A1 | Lubricating compositions containing ashless catalytic antioxidant additives | GPX4, SOD1, GPX1 | RAPGEF4 4264/4885PTGS2 1085/4885ALDH1A1 81/4885 |
| US-20110230680-A1 | LUBRICATING COMPOSITIONS CONTAINING ASHLESS CATALYTIC ANTIOXIDANT ADDITIVES | GPX4, SOD1, GPX1 | RAPGEF4 4163/4885PTGS2 1192/4885ALDH1A1 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.